Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026
Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Policy / Regulatory

NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026
Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026
Company Deals

Bide Pharmatech Set for IPO on Shanghai’s STAR Market

Fineline Cube Sep 15, 2022

Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...

Drug Policy / Regulatory

NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Sep 15, 2022

The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...

Company Drug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

Fineline Cube Sep 15, 2022

Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...

Policy / Regulatory

Guangdong Launches Free HPV Vaccination Program for School-aged Girls

Fineline Cube Sep 15, 2022

Guangdong province has rolled out a free HPV vaccination program this month, aimed at improving...

Company Drug

Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis

Fineline Cube Sep 15, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...

Policy / Regulatory

Hubei Province Proposes National TCM Patent Medicine Procurement Alliance

Fineline Cube Sep 15, 2022

The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...

Company Drug

Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study

Fineline Cube Sep 15, 2022

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...

Company Drug

CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment

Fineline Cube Sep 15, 2022

The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...

Company Drug

Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study

Fineline Cube Sep 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Drug

I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial

Fineline Cube Sep 14, 2022

China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...

Company Drug

Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...

Company Drug

Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod

Fineline Cube Sep 14, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...

Company Deals

Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital

Fineline Cube Sep 14, 2022

China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions”...

Company Policy / Regulatory

NMPA Issues Guidelines on Medical Device Grading Administration

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) has released a set of Guiding Opinions on “Medical...

Policy / Regulatory

Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review

Fineline Cube Sep 14, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...

Company Drug

Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study

Fineline Cube Sep 14, 2022

China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...

Company Deals

Hengrui Medicine to Incentivize Employees with Share Distribution

Fineline Cube Sep 14, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...

Policy / Regulatory

Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise

Fineline Cube Sep 13, 2022

US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...

Company Deals

QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China

Fineline Cube Sep 13, 2022

UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure...

Company Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study

Fineline Cube Sep 13, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...

Posts pagination

1 … 622 623 624 … 663

Recent updates

  • Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms
  • Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor
  • Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.